Developer docs
API playgroundTry for free, no card

Search company profiles

ProTom International

Full company profile

uuid0002l4v

Namestring
ProTom International
Legal namestring
ProTom International Holding Corporation
Company typeenum
Private
Founded yearint
2008
Descriptiontext

ProTom International Holding Corporation is a U.S.-based medical device manufacturer founded in 2008 that develops and commercializes proton therapy systems for cancer treatment. The company's product portfolio centers on the Radiance330 and Radiance330-c proton therapy systems, both of which have achieved full U.S. FDA 510(k) clearance. These systems are built on proprietary synchrotron-based proton acceleration technology combined with pencil beam scanning capability, designed to deliver precise tumor targeting while addressing the high cost and complexity traditionally associated with proton therapy installations.

The company generates revenue through two primary streams: capital sales of Radiance330 systems to hospitals and cancer treatment centers, and recurring long-term service and maintenance contracts that support debt service obligations. Pricing is not publicly disclosed, and the company employs an enterprise field sales motion targeting radiation oncology departments and dedicated cancer treatment facilities.

ProTom International operates a globally distributed commercial structure. Its wholly-owned subsidiary ProTom Asia Limited, headquartered in Tsuen Wan, Hong Kong, serves as the exclusive licensee covering China (including Hong Kong, Macau, and Taiwan), North Asia, South Asia, the Middle East, and Africa — with rights to manufacture, assemble, and test products in those territories. The company's U.S. headquarters is in Flower Mound, Texas. To date, ProTom has secured only "prestigious initial site installations," and its most recent disclosed funding was a $30 million round in April 2017.

Short descriptiontext

ProTom International is a U.S. medical device manufacturer founded in 2008 that develops FDA 510(k)-cleared proton therapy systems (Radiance330 and Radiance330-c) using synchrotron and pencil beam scanning technology, selling to hospitals and cancer treatment centers globally via a Hong Kong-based exclusive Asian licensee.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
proton therapy systems, radiation oncology equipment, cancer treatment technology, medical particle therapy, synchrotron proton systems
Industry2 codes
PRIMARYHLAKAFAC
Radiation Oncology
SECONDARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Medical Radiation Therapy Equipment
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Proton Therapy System Sales
TypeHardware Sales
Description

Sale of Radiance330 proton therapy systems to hospitals and cancer treatment centers. The company has achieved FDA 510(k) clearance enabling commercial deployment.

protomasia.com
2Long-term Service Contracts
TypeSubscription Recurring
Description

Ongoing service and maintenance contracts that provide recurring revenue stream and ability to serve debt.

protomasia.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Radiance330
Description

Proton therapy system product line

protomasia.com
+1 more record
Core offering1 text field

ProTom International designs, manufactures and sells proton therapy systems—principally the Radiance330 and the compact Radiance330-c—that use synchrotron-based proton acceleration and pencil beam scanning to deliver precision radiation therapy to cancer patients. The company supports its installed base with long-term service and maintenance contracts that generate recurring post-installation revenue.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ProTom International Holding Corporation is a provider of cost-effective, commercially viable proton therapy systems. The company's product portfolio centers on the Radiance330 and Radiance330-c proton therapy systems, both of which have achieved full U.S. FDA 510(k) clearance. These systems utilize advanced technologies including Pencil Beam Scanning and Synchrotron Technology for precise tumor targeting in radiation therapy treatments.

Product and service2 records
1Radiance330 Proton Therapy System
CategoryMedical Radiation Therapy Equipment
Description

Proton therapy system providing cost-effective, commercially viable radiation treatment for cancer patients, with full U.S. FDA 510(k) clearance, proprietary synchrotron technology and pencil beam scanning for precise tumor targeting. Targeted at hospitals and cancer treatment centers.

2Radiance330-c Compact Proton Therapy System
CategoryMedical Radiation Therapy Equipment
Description

Compact variant of the Radiance proton therapy system designed for facilities with space constraints while maintaining clinical efficacy and full FDA 510(k) clearance. Targeted at hospitals and cancer treatment centers needing smaller-footprint proton therapy installations.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1ProTom Asia Limited
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

ProTom Asia Limited is the exclusive licensee of ProTom International of USA for territories of China (including Hong Kong, Macau and Taiwan), North Asia, South Asia, the Middle East and Africa countries for all products, use of technologies, use of IP as well as manufacturing, assembly and testing of the products. This partnership enables regional manufacturing, sales, and service operations across the licensed territories.

protomasia.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1IBA (Ion Beam Applications)
TypeDirect peer
Description

IBA is the global market leader in proton therapy systems, offering ProteusONE and ProteusPLUS solutions. It is the most direct competitor to ProTom's Radiance330 in the proton therapy equipment category, with overlapping customers (hospitals and cancer centers) and similar synchrotron/cyclotron-based technology approaches.

TypeDirect peer
Description

Mevion develops compact proton therapy systems (MEVION S250i with HYPERSCAN pencil beam scanning) targeting the same cost-conscious, space-constrained hospital segment that ProTom addresses with Radiance330-c. It is the closest direct competitor in the compact proton therapy sub-segment.

TypeDirect peer
Description

Hitachi manufactures proton and carbon ion therapy systems installed globally, competing head-to-head with ProTom in hospital cancer center sales. Both companies target the same radiation oncology buyer with synchrotron-based particle therapy technology.

TypeDirect peer
Description

Sumitomo Heavy Industries manufactures proton therapy systems, primarily for the Japanese market but also internationally. It competes with ProTom in the synchrotron-based proton therapy equipment category serving hospitals and cancer treatment centers.

TypeBroad incumbent
Description

Varian, now part of Siemens Healthineers, is a dominant radiation oncology equipment provider offering linacs, proton therapy (ProBeam), and software solutions. It competes with ProTom in proton therapy while also serving the broader radiotherapy market that ProTom does not address.

TypeBroad incumbent
Description

Elekta is a leading provider of radiation therapy and radiosurgery equipment (Elekta Unity, Versa HD, Gamma Knife) and oncology software. It competes indirectly with ProTom by offering alternative advanced radiotherapy modalities that hospitals may choose over proton therapy.

TypeEmerging player
Description

Accuray develops the CyberKnife and TomoTherapy systems for precision radiation therapy, competing for hospital capital budgets that might otherwise fund proton therapy. It represents an alternative modality competing for the same oncology treatment share.

TypeEmerging player
Description

ViewRay pioneered MR-guided radiation therapy with its MRIdian system, offering an alternative advanced modality that competes with proton therapy for hospital cancer center capital dollars. It overlaps with ProTom in targeting precision oncology treatment positioning.

TypeOthers
Description

Philips provides radiation oncology treatment planning software and imaging solutions that integrate with proton therapy systems including those from ProTom. It is an adjacent ecosystem participant rather than a direct equipment competitor, but competes for hospital oncology capital budgets.

TypeOthers
Description

GE HealthCare supplies diagnostic imaging, simulation, and oncology workflow software used alongside proton therapy installations. It is an adjacent ecosystem participant rather than a direct competitor, but addresses overlapping hospital oncology capital budgets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProTom International

Medical Radiation Therapy Equipmentprotominternational.com

ProTom International is a U.S. medical device manufacturer founded in 2008 that develops FDA 510(k)-cleared proton therapy systems (Radiance330 and Radiance330-c) using synchrotron and pencil beam scanning technology, selling to hospitals and cancer treatment centers globally via a Hong Kong-based exclusive Asian licensee.

What ProTom International does

ProTom International Holding Corporation is a U.S.-based medical device manufacturer founded in 2008 that develops and commercializes proton therapy systems for cancer treatment. The company's product portfolio centers on the Radiance330 and Radiance330-c proton therapy systems, both of which have achieved full U.S. FDA 510(k) clearance. These systems are built on proprietary synchrotron-based proton acceleration technology combined with pencil beam scanning capability, designed to deliver precise tumor targeting while addressing the high cost and complexity traditionally associated with proton therapy installations.

The company generates revenue through two primary streams: capital sales of Radiance330 systems to hospitals and cancer treatment centers, and recurring long-term service and maintenance contracts that support debt service obligations. Pricing is not publicly disclosed, and the company employs an enterprise field sales motion targeting radiation oncology departments and dedicated cancer treatment facilities.

ProTom International operates a globally distributed commercial structure. Its wholly-owned subsidiary ProTom Asia Limited, headquartered in Tsuen Wan, Hong Kong, serves as the exclusive licensee covering China (including Hong Kong, Macau, and Taiwan), North Asia, South Asia, the Middle East, and Africa — with rights to manufacture, assemble, and test products in those territories. The company's U.S. headquarters is in Flower Mound, Texas. To date, ProTom has secured only "prestigious initial site installations," and its most recent disclosed funding was a $30 million round in April 2017.

ProTom International firmographics

Firmographics
Name
ProTom International
Legal name
ProTom International Holding Corporation
Website
https://protominternational.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
ProTom International is a U.S. medical device manufacturer founded in 2008 that develops FDA 510(k)-cleared proton therapy systems (Radiance330 and Radiance330-c) using synchrotron and pencil beam scanning technology, selling to hospitals and cancer treatment centers globally via a Hong Kong-based exclusive Asian licensee.
Ownership category
akta.pro rank

ProTom International industry classification

Industry
Product category
Medical Radiation Therapy Equipment
NAICS
Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)
SIC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLAKAFAC
Radiation Oncology
SECONDARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Proton therapy systems
  • Radiation oncology equipment
  • Cancer treatment technology
  • Medical particle therapy
  • Synchrotron proton systems

Where ProTom International is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices2 records

Markets served

ProTom International business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Proton Therapy System Sales: Sale of Radiance330 proton therapy systems to hospitals and cancer treatment centers. The company has achieved FDA 510(k) clearance enabling commercial deployment.
  2. Long-term Service Contracts: Ongoing service and maintenance contracts that provide recurring revenue stream and ability to serve debt.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

ProTom International product offering

Product offering

Core offering

ProTom International designs, manufactures and sells proton therapy systems—principally the Radiance330 and the compact Radiance330-c—that use synchrotron-based proton acceleration and pencil beam scanning to deliver precision radiation therapy to cancer patients. The company supports its installed base with long-term service and maintenance contracts that generate recurring post-installation revenue.

Product overview

ProTom International Holding Corporation is a provider of cost-effective, commercially viable proton therapy systems. The company's product portfolio centers on the Radiance330 and Radiance330-c proton therapy systems, both of which have achieved full U.S. FDA 510(k) clearance. These systems utilize advanced technologies including Pencil Beam Scanning and Synchrotron Technology for precise tumor targeting in radiation therapy treatments.

Differentiator

Problem solved

Functional benefit

Brands

  • Radiance330: Proton therapy system product line
  • Radiance330-c

Products and services

  • Radiance330 Proton Therapy System Proton therapy system providing cost-effective, commercially viable radiation treatment for cancer patients, with full U.S. FDA 510(k) clearance, proprietary synchrotron technology and pencil beam scanning for precise tumor targeting. Targeted at hospitals and cancer treatment centers.
  • Radiance330-c Compact Proton Therapy System Compact variant of the Radiance proton therapy system designed for facilities with space constraints while maintaining clinical efficacy and full FDA 510(k) clearance. Targeted at hospitals and cancer treatment centers needing smaller-footprint proton therapy installations.

Companies that use ProTom International

Customer profile

Segments1 record

Ideal customer profiles1 record

ProTom International technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ProTom International partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ProTom Asia LimitedcoreOEM/ Whitelabel/ Licensing PartnerProTom Asia Limited is the exclusive licensee of ProTom International of USA for territories of China (including Hong Kong, Macau and Taiwan), North Asia, South Asia, the Middle East and Africa countries for all products, use of technologies, use of IP as well as manufacturing, assembly and testing of the products. This partnership enables regional manufacturing, sales, and service operations across the licensed territories.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

ProTom International competitors and assessment

Company assessment

Direct peers

  • IBA (Ion Beam Applications): IBA is the global market leader in proton therapy systems, offering ProteusONE and ProteusPLUS solutions. It is the most direct competitor to ProTom's Radiance330 in the proton therapy equipment category, with overlapping customers (hospitals and cancer centers) and similar synchrotron/cyclotron-based technology approaches.
  • Mevion Medical Systems: Mevion develops compact proton therapy systems (MEVION S250i with HYPERSCAN pencil beam scanning) targeting the same cost-conscious, space-constrained hospital segment that ProTom addresses with Radiance330-c. It is the closest direct competitor in the compact proton therapy sub-segment.
  • Hitachi (Hitachi Particle Beam Therapy): Hitachi manufactures proton and carbon ion therapy systems installed globally, competing head-to-head with ProTom in hospital cancer center sales. Both companies target the same radiation oncology buyer with synchrotron-based particle therapy technology.
  • Sumitomo Heavy Industries: Sumitomo Heavy Industries manufactures proton therapy systems, primarily for the Japanese market but also internationally. It competes with ProTom in the synchrotron-based proton therapy equipment category serving hospitals and cancer treatment centers.

Broad incumbents

  • Varian Medical Systems (Siemens Healthineers): Varian, now part of Siemens Healthineers, is a dominant radiation oncology equipment provider offering linacs, proton therapy (ProBeam), and software solutions. It competes with ProTom in proton therapy while also serving the broader radiotherapy market that ProTom does not address.
  • Elekta: Elekta is a leading provider of radiation therapy and radiosurgery equipment (Elekta Unity, Versa HD, Gamma Knife) and oncology software. It competes indirectly with ProTom by offering alternative advanced radiotherapy modalities that hospitals may choose over proton therapy.

Emerging players

  • Accuray: Accuray develops the CyberKnife and TomoTherapy systems for precision radiation therapy, competing for hospital capital budgets that might otherwise fund proton therapy. It represents an alternative modality competing for the same oncology treatment share.
  • ViewRay: ViewRay pioneered MR-guided radiation therapy with its MRIdian system, offering an alternative advanced modality that competes with proton therapy for hospital cancer center capital dollars. It overlaps with ProTom in targeting precision oncology treatment positioning.

Others

  • Philips (Radiation Oncology Solutions): Philips provides radiation oncology treatment planning software and imaging solutions that integrate with proton therapy systems including those from ProTom. It is an adjacent ecosystem participant rather than a direct equipment competitor, but competes for hospital oncology capital budgets.
  • GE HealthCare: GE HealthCare supplies diagnostic imaging, simulation, and oncology workflow software used alongside proton therapy installations. It is an adjacent ecosystem participant rather than a direct competitor, but addresses overlapping hospital oncology capital budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

ProTom International social profiles

Digital presence

ProTom International compliance and trust

Trust signal

Compliance1 record

ProTom International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProTom International leadership team

Management profile

Number of profiles

Profiles6 records

ProTom International subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ProTom International funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProTom International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProTom International

What does ProTom International do?

ProTom International designs, manufactures and sells proton therapy systems—principally the Radiance330 and the compact Radiance330-c—that use synchrotron-based proton acceleration and pencil beam scanning to deliver precision radiation therapy to cancer patients. The company supports its installed base with long-term service and maintenance contracts that generate recurring post-installation revenue.

Is ProTom International a public or private company?

ProTom International is a private company. It is classified as unknown and is currently operating.

When was ProTom International founded?

ProTom International was founded in 2008. It employs 11 to 50 people.

Where is ProTom International based?

ProTom International is headquartered in Woburn, United States, in the North America region.

How does ProTom International make money?

Two revenue lines are on record. Proton Therapy System Sales are the primary driver. The others are long-term Service Contracts.

Who are ProTom International's main competitors?

Direct peers on record are IBA (Ion Beam Applications), Mevion Medical Systems, Hitachi (Hitachi Particle Beam Therapy) and Sumitomo Heavy Industries. Broad incumbents are Varian Medical Systems (Siemens Healthineers) and Elekta. Emerging players are Accuray and ViewRay. Others are Philips (Radiation Oncology Solutions) and GE HealthCare.

Does ProTom International have an API?

No public API is recorded for ProTom International.

What industry is ProTom International in?

ProTom International's product category is Medical Radiation Therapy Equipment. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim). Its NAICS code is 334517 and its SIC code is 3844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comLeading Companies Fueling Growth and Innovation in the Maprotiline Hydrochloride API MarketThe Business Research Company published a market research report on the Maprotiline Hydrochloride API market, projecting it to reach $1.64 billion by 2030 with a 6.4% compound annual growth rate, driven by demand for mental health therapies and API outsourcing trends. The report lists 20+ companies operating in this market segment, including Thermo Fisher Scientific, Lupin Limited, and Zydus Cadila. In December 2023, Codexis acquired a division of Nestlé Health Science for an undisclosed sum to advance its CDX-7109 asset, while ProTom International launched its Radiance 330 C proton therapy system in September 2024 as an example of broader medical technology innovation.PR NewswireGlobal Particle Therapy Market Report 2022-2027 Featuring Prominent Players - IBA Worldwide, Hitachi, Varian Medical Systems, Provision Healthcare, Optivus Proton Therapy and Protom InternationalResearchAndMarkets has released a report projecting the global particle therapy market to grow from USD 677 million in 2022 to USD 1,004 million by 2027 at a CAGR of 8.2%. The growth is primarily driven by the increasing prevalence of cancer and the clinical advantages of particle therapy over traditional photon treatments, with Asia Pacific expected to register the highest revenue growth.PR NewswireProTom International Signed a Strategic Distribution and Licensing Agreement to Distribute with GHGK in ChinaProTom International Holding Corporation signed an exclusive distribution and licensing agreement with Guohong Guokang (Beijing) Health Technology Development Co., LTD to distribute ProTom's Radiance 330 Proton Therapy System in mainland China. Under the agreement, GHGK gains exclusive rights to distribute the system in China with potential expansion to other countries over time, and both companies will co-market the product in Asia-Pacific regions. The deal represents ProTom's continued international expansion as a proton therapy system provider, with the goal of improving access to advanced cancer treatment for patients in China and surrounding Asian regions.PR NewswireProTom International Welcomes the South Australian Government's Announcement of the Commencement of Work on the Australian Bragg CentreProTom International announced it will install its Radiance 330® Proton Therapy System at the new Australian Bragg Centre in Adelaide, South Australia, making it the first clinically dedicated proton therapy center in Australia and the Southern Hemisphere. The facility, expected to begin operations in 2024, will be built within SAHMRI 2 and include two gantries, one fixed beam line, and a research port. The Bragg Centre will serve as both a clinic and research facility, partnering with SAHMRI to bring advanced proton therapy to cancer patients across the Asia-Pacific region.PR NewswireProTom Receives U.S. FDA 510(k) Clearance for Its Radiance 330® Single Room Proton Therapy SystemProTom International Holding Corporation received 510(k) clearance from the U.S. Food and Drug Administration for its Radiance 330 proton therapy system installed at Massachusetts General Hospital. The compact system utilizes advanced pencil beam scanning technology and requires significantly less radiation shielding than traditional installations. This regulatory approval marks a key milestone in ProTom's mission to expand access to targeted cancer treatment by reducing the cost and footprint of proton therapy facilities.